Who are ANASTROZOLE's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Kisqali, Aromasin, Femara, Arimidex, Actinex, Cytadren.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/chembl-chembl1399.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

ANASTROZOLE — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ANASTROZOLE (ANASTROZOLE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Aromatase Inhibitor [EPC].

marketed Aromatase Inhibitor [EPC] aromatase Small molecule Live · refreshed every 30 min

Target snapshot

ANASTROZOLE (ANASTROZOLE). Anastrozole inhibits the aromatase enzyme, reducing estrogen levels which can stimulate breast cancer growth.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ANASTROZOLE TARGET	ANASTROZOLE		marketed	Aromatase Inhibitor [EPC]	aromatase	1995-01-01
Kisqali	ribociclib	Novartis	marketed	CDK4/6 inhibitor; aromatase inhibitor	Cyclin-dependent kinase (CDK) 4 and 6; aromatase enzyme	2017-01-01
Aromasin	exemestane	Pfizer	marketed	Aromatase Inhibitor [EPC]	Aromatase	1999-01-01
Femara	letrozole	Novartis AG	marketed	Aromatase Inhibitor [EPC]	aromatase enzyme	1997-07-25
Arimidex	anastrozole	AstraZeneca	marketed	Aromatase inhibitor	Aromatase enzyme	1995-12-27
Actinex	MASOPROCOL		marketed	masoprocol	Aromatase	1992-01-01
Cytadren	AMINOGLUTETHIMIDE	Novartis	marketed	Adrenal Steroid Synthesis Inhibitor	Aromatase	1980-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Aromatase Inhibitor [EPC] class)

· 2 drugs in this class
Al-Azhar University · 1 drug in this class
Novartis AG · 1 drug in this class
Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ANASTROZOLE — Competitive Intelligence Brief. https://druglandscape.com/ci/chembl-chembl1399. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing